Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Net Income (2019 - 2025)

Historic Net Income for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to -$38.5 million.

  • Legend Biotech's Net Income rose 6697.58% to -$38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$260.0 million, marking a year-over-year decrease of 3391.36%. This contributed to the annual value of -$139240.0 for FY2024, which is 9997.32% up from last year.
  • Legend Biotech's Net Income amounted to -$38.5 million in Q3 2025, which was up 6697.58% from -$124.2 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Net Income ranged from a high of $54738.0 in Q4 2024 and a low of -$403.6 million during Q4 2021
  • For the 5-year period, Legend Biotech's Net Income averaged around -$99.6 million, with its median value being -$91.6 million (2021).
  • In the last 5 years, Legend Biotech's Net Income crashed by 3228891.42% in 2022 and then soared by 13678.48% in 2024.
  • Over the past 5 years, Legend Biotech's Net Income (Quarter) stood at -$403.6 million in 2021, then surged by 66.41% to -$135.6 million in 2022, then surged by 99.89% to -$148806.0 in 2023, then skyrocketed by 136.78% to $54738.0 in 2024, then tumbled by 70356.49% to -$38.5 million in 2025.
  • Its Net Income stands at -$38.5 million for Q3 2025, versus -$124.2 million for Q2 2025 and -$97.3 million for Q1 2025.